Oorsprong van het eerstegraads netwerk van Juan Sabé Solé
| Entiteit | Type entiteit | Industrie | |
|---|---|---|---|
| Mutual Fd-Open End | Investment Trusts/Mutual Funds | 7 | |
Factotum Trading SICAV SA
 Factotum Trading SICAV SA Investment Trusts/Mutual FundsMiscellaneous Factotum Trading SICAV SA invests directly or indirectly in fixed-income securities, equity assets, stocks, and hedge funds. The company was founded on August 9, 2000 and is headquartered in Madrid, Spain.
4
| Mutual Fd-Open End | Investment Trusts/Mutual Funds | 4 |
Grafiek van bedrijven verbonden in de tweede graad
Connectie in verschillende bedrijven
Bedrijven verbonden met Juan Sabé Solé via zijn persoonlijke netwerk
| Onderneming | Sector | Gelieerde personen | Hoofdpost |
|---|---|---|---|
Inicio 2000, SICAV
 Inicio 2000, SICAV Investment Trusts/Mutual FundsMiscellaneous Inicio 2000 SICAV SA is an open-end investment fund which engages in providing equity securities services. It acquires, possesses, and issues securities and other financial assets. The company was founded on May 23, 2000 and is headquartered in Barcelona, Spain. | Investment Trusts/Mutual Funds | Director/Board Member | |
| SCHNELL VOYAGER 3 SICAV, SA | Investment Trusts/Mutual Funds | Director/Board Member | |
| Escuela Superior de Administración y Dirección de Empresas | College/University | Undergraduate Degree | |
GVC Gaesco Gestión SGIIC SA
 GVC Gaesco Gestión SGIIC SA Investment ManagersFinance GVC Gaesco Gestión SGIIC SA (GGC) is the wholly-owned fund management subsidiary of GVC Gaesco Holding SL in Spain. Formerly known as Gaesco Gestión SGIC, the firm was founded in 1985 and changed their name to GVC Gaesco Gestión in 2008 when they were acquired by GVC Gaesco Holding SL. GGC is headquartered in Barcelona and manages a range of funds for private and institutional investors. | Investment Managers | Chief Executive Officer Chairman | |
SOM Innovation Biotech SA
 SOM Innovation Biotech SA Pharmaceuticals: MajorHealth Technology SOM Innovation Biotech SA engages in the discovery and development of new indications for known drugs. Its pipeline consists of repositioned compounds for the treatment of amyloidosis, huntington's disease, hyperplasia, glioblastoma, and alzheimer's disease. The company was founded by Raul Insa Boronat and Ignasi Belda Reig on December 30, 2009 and is headquartered in Barcelona, Spain. | Pharmaceuticals: Major | Director/Board Member | |
| OPTIMUM RE SPAIN, SOCIMI, S.A. | Real Estate Development | Director/Board Member |
Statistieken
Internationaal
| Spanje | 9 |
| Argentinië | 2 |
Sectoraal
| Miscellaneous | 5 |
| Finance | 4 |
| Consumer Services | 2 |
| Health Technology | 2 |
Operationeel
| Director/Board Member | 10 |
| Corporate Secretary | 6 |
| President | 5 |
| Chief Executive Officer | 4 |
| Chief Investment Officer | 2 |
Sterkste connecties
- Beurs
- Insiders
- Juan Sabé Solé
- Bedrijfsconnecties
